What are the most important things to know about lamivudine?
Lamivudine can cause serious, life-threatening side effects. These include a buildup ofin the blood ( ), severe problems, and inflammation of the ( ) in children at risk for developing pancreatitis.
Contact your health care provider right away if you have any of the following symptoms that could be signs of lactic acidosis:
- Feeling very weak or tired
- Unusual muscle pain
- Trouble breathing
- Stomach pain with nausea and vomiting
- Feeling cold, especially in your arms and legs
- Feeling dizzy or light-headed
- Fast or irregular heartbeat
Contact your health care provider right away if you have any of the following symptoms that could be signs of severe liver problems:
- Yellowing of your skin or the whites of your eyes ( )
- Dark-colored urine
- Light-colored bowel movements
- Loss of appetite for several days or longer
- Pain, aching, or tenderness on the right side of your stomach area
Call your health care provider right away if your child develops signs and symptoms of pancreatitis, including severe pain in the upper stomach area with or without nausea and vomiting.
If you have both HIV and(HBV) and take lamivudine, your HBV may get much worse (flare up) if you stop taking lamivudine. Do not stop taking lamivudine without first talking to your health care provider.
Epivir-HBV is a different type of lamivudine used to treat chronic HBV infection. You should not take Epivir-HBV if you have or may have HIV infection. Epivir-HBV does not contain enough lamivudine to effectively treat HIV infection. If you have both HIV and HBV, you should not use Epivir-HBV to treat your infections.
While taking lamivudine, it is important to keep all of your appointments with your health care provider.
What is lamivudine?
Lamivudine is a prescription medicine approved by the U.S.(FDA) for the treatment of HIV infection in adults and children 3 months of age and older. Lamivudine is always used in combination with other HIV medicines.
HIV medicines can’t cure HIV/AIDS, but taking HIV medicines every day helps people with HIV live longer, healthier lives. HIV medicines also reduce the risk of HIV. If you are taking HIV medicines, including lamivudine, don’t cut down on, skip, or stop taking them unless your health care provider tells you to.
Lamivudine is also effective against HBV section of the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV.B infection (HBV) in combination with other drugs and may be included in the HIV regimen of a person living with both HIV and HBV. However, if you have both HIV and HBV infection and take lamivudine, your HBV infection may get much worse (flare up) if you stop taking lamivudine. Do not stop taking lamivudine without first talking to your health care provider. For more information on the HBV-related use of lamivudine, please refer to the
Epivir-HBV is a different type of lamivudine approved by FDA for the treatment of chronic HBV infection in adults and children 2 years of age and older. You should not take Epivir-HBV if you have or may have HIV infection.
What should I tell my health care provider before taking lamivudine?
Before taking lamivudine, tell your health care provider:
- If you are allergic to lamivudine or any other medicines.
- If you have or have had liver problems, including hepatitis B virus infection (HBV) or (HCV).
- If you have kidney problems.
- If you have . Each 15-mL (150 mg) of lamivudine oral solution contains three grams of sucrose (common table sugar).
- If you have any other medical conditions.
- If you are pregnant or plan to become pregnant. Talk to your health care provider about the risks and benefits of taking lamivudine during pregnancy.
- If you are breastfeeding or plan to breastfeed. Do not breastfeed if you have HIV or are taking lamivudine.
- If you are using HIV and Birth Control infographic. -based birth control (such as pills, implants, or vaginal rings). For more information about using birth control and HIV medicines at the same time, view the
- About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products you are taking or plan to take. Lamivudine may affect the way other medicines or products work, and other medicines or products may affect how lamivudine works. Taking lamivudine together with certain medicines or products may cause serious, life-threatening side effects.
How should I take lamivudine?
Lamivudine (brand name: Epivir) comes in the following forms and strengths:
- 150-mg tablets
- 300-mg tablets
- 10-mg/mL oral solution
Take lamivudine according to your health care provider’s instructions.
For children 3 months and older, their health care provider will prescribe a dose of lamivudine based on their body weight.
Take lamivudine by mouth, with or without food. Tell your health care provider if you or your child has trouble swallowing tablets. Lamivudine also comes as a liquid oral solution.
Always take lamivudine in combination with other HIV medicines.
If you take too much lamivudine, contact your health care provider or local poison control center (1-800-222-1222) right away, or go to the nearest hospital emergency room.
For more information on how to take lamivudine, see the FDA drug label.
What should I do if I forget a dose?
If you miss a dose of lamivudine, take the missed dose as soon as you remember it. But if it is almost time for your next dose, skip the missed dose and just take your next dose at the regular time. Do not take two doses at the same time to make up for a missed dose.
What side effects can lamivudine cause?
Lamivudine may cause side effects. Many side effects from HIV medicines, such as nausea or occasional dizziness, are manageable. See the ClinicalInfo fact sheet on HIV Medicines and Side Effects for more information.
Some side effects of lamivudine can be serious. Serious side effects of lamivudine include a buildup of lactic acid in the blood (lactic acidosis), severe liver problems, and inflammation of the pancreas (pancreatitis) in children at risk for developing pancreatitis.
Another possible side effect of lamivudine is changes in your(called or IRIS). IRIS is a condition that sometimes occurs when the immune system begins to recover after treatment with an HIV medicine. As the immune system gets stronger, it may have an increased response to a previously hidden infection.
Tell your health care provider if you have any side effect that bothers you or that does not go away.
These are not all the possible side effects of lamivudine. To learn more about possible side effects of lamivudine, read the drug label orYou can report side effects to FDA at 1-800-FDA-1088 (1-800-332-1088) or or talk to your health care provider or pharmacist.online.
How should lamivudine be stored?
- Store lamivudine tablets and oral solution at room temperature, 68°F to 77°F (20°C to 25°C).
- Keep lamivudine oral solution in the container that it came in and keep the container tightly closed.
- Do not use lamivudine if the original seal over the container opening is broken or missing.
- Throw away lamivudine that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
- Keep lamivudine and all medicines out of reach of children.
Where can I find more information about lamivudine?
More information about lamivudine is available:
- The lamivudine drug label. The Patient Counseling Information section of the label includes information for people taking lamivudine.
- Recommendations on the use of lamivudine from the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV, prepared by the , the , and the HIV Medicine Association of the Diseases Society of America.
- Lamivudine-related research studies, from the ClinicalInfo database of study summaries.
- A list of FDA-approved HIV medicines, from ClinicalInfo
Main number: 877-844-8872
Patient assistance (ViiV Connect): 844-588-3288
The above Patient Version drug summary is based on the following FDA label(s): Solution, tablet (film coated).
Last Reviewed: June 17, 2020